We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

Back to rankings

38 hedge funds and large institutions have $161M invested in Strongbridge Biopharma plc. in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

475% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 4

100% more funds holding

Funds holding: 19 → 38 (+19)

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

62% more capital invested

Capital invested by funds: $99.4M → $161M (+$61.4M)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
38
Holders Change
+19
Holders Change %
+100%
% of All Funds
0.95%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
23
Increased
4
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4M
2
Northern Trust
Northern Trust
Illinois
+$945K
3
NC
Nexthera Capital
New York
+$309K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$307K
5
TCIM
TIAA CREF Investment Management
New York
+$290K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$507K
2
GPCM
Granite Point Capital Management
Massachusetts
-$125K
3
Millennium Management
Millennium Management
New York
-$104K
4
SIM
Spark Investment Management
New York
-$91K
5
Barclays
Barclays
United Kingdom
-$70.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
26
American International Group
New York
$97K +$62.9K +13,599 New
NFA
27
Nationwide Fund Advisors
Ohio
$86K +$55.7K +12,049 New
CCM
28
Consonance Capital Management
New York
$72K – – –
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$61K +$39.3K +8,500 New
SO
30
STRS Ohio
Ohio
$45K +$29.6K +6,400 New
Legal & General Group
31
Legal & General Group
United Kingdom
$23K +$14.7K +3,181 New
PAM
32
Panagora Asset Management
Massachusetts
$17K +$10.9K +2,351 New
BNP Paribas Financial Markets
33
BNP Paribas Financial Markets
France
$16.4K +$10.6K +2,297 New
AIP
34
Ameritas Investment Partners
Nebraska
$14K +$8.89K +1,924 New
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$7K -$356 -77 -8%
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$1K +$342 +74 New
MAM
37
Meeder Asset Management
Ohio
$1K +$883 +191 New
Millennium Management
38
Millennium Management
New York
– -$104K -21,952 Closed
SIM
39
Spark Investment Management
New York
– -$91K -19,200 Closed
Barclays
40
Barclays
United Kingdom
– -$70.7K -15,297 -100%
BCM
41
BlueCrest Capital Management
Jersey
– -$54K -11,394 Closed
SCM
42
Segantii Capital Management
Hong Kong
– -$36K -7,600 Closed
1
2

SBBP Hedge Fund Activity: Q2 2017 in Review

38 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q2 2017, worth a combined $161M — up 62% from $99.4M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new SBBP positions and 4 closed out — a net gain of 19 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $4M. The largest seller was Broadfin Capital, cutting an estimated $507K.

  • 38 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q2 2017, up from 19 in Q1 2017.
  • Funds reported $161M of Strongbridge Biopharma plc. stock for Q2 2017, up 62% quarter-over-quarter.
  • 23 funds opened new Strongbridge Biopharma plc. positions in Q2 2017 and 4 closed out, a net change of +19 holders.
  • The largest Strongbridge Biopharma plc. buyer in Q2 2017 was BlackRock, an estimated $4M added.
  • The largest Strongbridge Biopharma plc. seller in Q2 2017 was Broadfin Capital, an estimated $507K sold.

Based on aggregated 13F filings for Q2 2017.